dualyx
dualyx is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at dualyx.
dualyx is a company.
Key people at dualyx.
Dualyx is a Ghent, Belgium-based biotech company developing next-generation immune modulators, primarily novel Treg-based therapies targeting autoimmune diseases.[1][2][3] Its lead program, DT-001, is an antibody agonist for TNF receptor 2 (TNFR2), which selectively expands regulatory T cells (Tregs) to suppress immune overactivity, with additional preclinical pipeline candidates like DT-002 and DT-003.[3][4][7] Dualyx serves patients with hard-to-treat autoimmune disorders, addressing unmet needs in immune modulation by progressing therapies from preclinical stages toward clinical proof-of-concept.[2][3] In May 2023, it raised €40 million ($44 million) in a Series A round co-led by Forbion, Andera Partners, and Fountain Healthcare Partners, supported by existing investors including BGV, V-Bio Ventures, PMV, VIB, HTGF, and GFF, following a €7 million seed round; funds support IND-enabling studies for DT-001 and pipeline expansion.[2][3][4]
Dualyx was founded in 2021 by CSO Luc Van Rompaey through a collaborative model involving Wurzburg University, argenx, VIB, Ghent University, and KU Leuven.[2][4] The idea emerged from expertise in antibody technology and Treg biology, focusing on TNFR2 as a "master control switch" for immune suppression.[2][3][4] Early traction came via a €7 million seed round from European life sciences investors, enabling preclinical validation of DT-001's selective Treg expansion across species.[2][4] Leadership includes CEO Wouter Verhoeven, with recent additions like Independent Chairman Bernard Coulie (CEO of Pliant Therapeutics) and board members Juliette Audet (Forbion) and Aneta Sottil (Andera Partners).[2][3][4]
Dualyx rides the surging wave of Treg-focused immunomodulation in autoimmune diseases, a trend fueled by limitations of existing therapies like JAK inhibitors and anti-TNFs, which often lack selectivity and long-term efficacy.[2][3] Timing aligns with advances in antibody engineering and growing recognition of TNFR2 as a key Treg regulator, amid a booming biotech investment in precision immunology post-2020s funding resurgence.[2][4] Market forces favoring Dualyx include rising autoimmune prevalence (e.g., rheumatoid arthritis, IBD), regulatory emphasis on novel mechanisms, and Europe's strong life sciences ecosystem in Belgium/Netherlands/Germany.[1][2] It influences the ecosystem by validating academic-industry collaborations and drawing capital to Treg assets, potentially accelerating competitors and setting benchmarks for preclinical-to-clinical transitions.[2][4]
Dualyx is poised to advance DT-001 into IND submission and early clinical trials within 1-2 years, leveraging Series A funds for proof-of-concept data that could validate TNFR2 agonists and unlock follow-on financing.[3][4] Key trends shaping its path include AI-driven antibody optimization, combination therapies with checkpoint inhibitors, and expanding autoimmune indications amid a projected $150B+ market.[7] Its influence may grow through partnerships or acquisitions by big pharma seeking next-gen immunology, evolving from preclinical innovator to clinical leader—building on its strong 2023 funding momentum to tackle unmet needs in immune diseases.[2][3]
Key people at dualyx.
